Skip to Main Content

Author Details

Rene Gonzalez
University of Colorado Anschutz Medical Campus
1990
165
64
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36378549Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma.Clin Cancer Res2023
37345092Introduction of a Polyethylene Glycol Linker Improves Uptake of <sup>67</sup>Cu-NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide in Melanoma.Cancers (Basel)2023
37140963Effects of Polyethylene Glycol and 8-Aminooctanoic Acid Linkers on Melanoma Uptake of [<sup>99m</sup>Tc]Tc-Tricarbonyl-NOTA-Conjugated Lactam-Cyclized α-MSH Peptides.Bioconjug Chem2023
34537899Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection.Ann Surg Oncol2022
35475603Novel Al<sup>18</sup>F-NOTA-Conjugated Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptides with Enhanced Melanoma Uptake.Bioconjug Chem2022
35486894Novel <sup>64</sup>Cu-Labeled NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Enhanced Tumor to Kidney Uptake Ratios.Mol Pharm2022
34762521The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of <sup>67</sup>Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides.Cancer Biother Radiopharm2022
34818112Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.J Clin Oncol2022
33234846Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).Melanoma Res2021
34326162Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.Cancer Discov2021
33087417Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft.Mol Cancer Res2021
32673170Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629).J Clin Oncol2020
31732523Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma.Clin Cancer Res2020
32062691Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.Cancer Chemother Pharmacol2020
33141072Facile preparation of a novel Ga-67-labeled NODAGA-conjugated lactam-cyclized alpha-MSH peptide at room temperature for melanoma targeting.Bioorg Med Chem Lett2020
33067454Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity.Nat Commun2020
32663011Novel [<sup>99m</sup>Tc]-Tricarbonyl-NOTA-Conjugated Lactam-Cyclized Alpha-MSH Peptide with Enhanced Melanoma Uptake and Reduced Renal Uptake.Mol Pharm2020
32708981Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.Cancers (Basel)2020
31171876Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.Nat Med2019
31644317Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptide.Cancer Biother Radiopharm2019
31781510IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients.Front Oncol2019
31602665A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making.J Surg Oncol2019
31562797Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.N Engl J Med2019
30870269Inflammatory side effects of BRAF and MEK inhibitors.Melanoma Res2019
30811280Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.J Clin Oncol2019
30777131Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.J Immunother Cancer2019
30763112Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting.Mol Pharm2019
29054983ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> Isoforms.Mol Cancer Ther2018
29909499Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases.J Neurooncol2018
30121453Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.Int Immunopharmacol2018
30404861[68]Ga-DOTA-GGNle-CycMSHhex targets the melanocortin-1 receptor for melanoma imaging.Sci Transl Med2018
30361170Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.Lancet Oncol2018
29402264Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.BMC Cancer2018
28991513Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.J Clin Oncol2018
27993793Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.Ann Oncol2017
28296713Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.Melanoma Res2017
28961465Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.Eur J Cancer2017
29076950Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.Melanoma Res2017
28651159Health-related quality of life results from the phase III CheckMate 067 study.Eur J Cancer2017
28891423Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.N Engl J Med2017
28841387Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.J Clin Oncol2017
28889792Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.N Engl J Med2017
27864876Kinase gene fusions in defined subsets of melanoma.Pigment Cell Melanoma Res2017
27916626Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>.Clin Genitourin Cancer2017
26811525Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.J Clin Oncol2016
26440571Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.Nucl Med Commun2016
27660706A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.J Immunother Cancer2016
27714434Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.Cancer Immunol Immunother2016
27496110NCCN Guidelines Insights: Melanoma, Version 3.2016.J Natl Compr Canc Netw2016
26981242Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.J Immunother Cancer2016
  • 1 - 50 of 165

Recommended Authors

Malaka Ameratunga
Australia Central Clinical School, Monash University
Career Start Year 2014
Number of shared co-authors 0
Manoela Tiago
Thomas Jefferson University
Career Start Year 2011
Number of shared co-authors 4
Gareth Rivalland
Auckland City Hospital
Career Start Year 2010
Number of shared co-authors 1
Anusha Kalbasi
Stanford Cancer Institute, Stanford School of Medicine
Career Start Year 2010
Number of shared co-authors 5
Jesse M Zaretsky
University of California los angeles
Career Start Year 2007
Number of shared co-authors 5
Harriet M Kluger
Yale School of Medicine
Career Start Year 2003
Number of shared co-authors 14
Mark E Smolkin
University of Virginia
Career Start Year 2002
Number of shared co-authors 2
Chi-Ping Day
Center for Cancer Research, National Cancer Institute
Career Start Year 2002
Number of shared co-authors 3
Daniela Mihic-Probst
University Hospital Zurich
Career Start Year 2001
Number of shared co-authors 4
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 4
Yardena Samuels
Weizmann Institute of Science
Career Start Year 1998
Number of shared co-authors 15
Michael A Davies
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 24
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 3
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 8
Andrew E Aplin
Thomas Jefferson University
Career Start Year 1996
Number of shared co-authors 12
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 5
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 1
David M Peereboom
Brain Tumor & Neuro-Oncology Cleveland Clinic Main Campus
Career Start Year 1993
Number of shared co-authors 0
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 1
Vera J Suman
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 3
Ashani T Weeraratna
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Career Start Year 1992
Number of shared co-authors 12
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 4
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 3
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 1
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 2
Craig L Slingluff
University of Virginia
Career Start Year 1987
Number of shared co-authors 10
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 6
Menashe Bar-Eli
The University of Texas MD Anderson Cancer Center
Career Start Year 1975
Number of shared co-authors 4
Meenhard Herlyn
Ellen and Ronald Caplan Cancer Center, The Wistar Institute
Career Start Year 1972
Number of shared co-authors 21

Collaborators

William A Robinson
National Centre for Asbestos Related Diseases, University of Western Australia
Co-authored papers 44
Martin D McCarter
University of Colorado School of Medicine
Co-authored papers 23
Dirk Schadendorf
Co-authored papers 14
Antoni Ribas
University of California Los Angeles (university of california los angeles)
Co-authored papers 14
Georgina V Long
Co-authored papers 14
John M Kirkwood
UPMC Hillman Cancer Center
Co-authored papers 12
Anna C Pavlick
Co-authored papers 11
Grant A McArthur
University of Melbourne
Co-authored papers 11
Reinhard Dummer
University Hospital Zurich
Co-authored papers 9
Caroline Robert
Co-authored papers 6
Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Co-authored papers 6
Bartosz Chmielowski
Jonsson Comprehensive Cancer Center, University of California Los Angeles
Co-authored papers 6
Steven E Robinson
University of Colorado Anschutz Medical Campus
Co-authored papers 6
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Co-authored papers 5
Dexiang Gao
University of Colorado Anschutz Medical Campus
Co-authored papers 5
Peter Hersey
Co-authored papers 4
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Dave S B Hoon
Saint John's Cancer Institute at Saint John's Health Center
Co-authored papers 4
Kimberly R Jordan
University of Colorado Anschutz Medical Campus
Co-authored papers 3
Robert W Williams
Mayo Clinic
Co-authored papers 3
Anthony J Greisinger
Co-authored papers 3
Rafia Bhore
Regeneron Pharmaceuticals
Co-authored papers 2
Donald L Morton
Co-authored papers 2
Richard W Joseph
Mayo Clinic Hospital
Co-authored papers 2
Damien Kee
Co-authored papers 2
Neeraj Agarwal
Co-authored papers 2
Hussein A Tawbi
MD Anderson Cancer Center
Co-authored papers 2
Takami Sato
Sidney Kimmel Cancer Center, Thomas Jefferson University
Co-authored papers 2
Joel M Baumgartner
University of California
Co-authored papers 2
Christopher L Corless
Oregon Health & Science University
Co-authored papers 2
Release 1.2